FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387160191> ?p ?o ?g. }

• W4387160191 endingPage "e609" @default.
• W4387160191 startingPage "e608" @default.
• W4387160191 abstract "Various methods to identify candidates for treatment deintensification with p16+ oropharyngeal squamous cell carcinoma (OPSCC) have been used, but the optimal approach is unknown.Multi-institutional cohort study of 385 patients with previously untreated p16+ OPSCC undergoing definitive radiotherapy (RT) with or without systemic therapy between 2009-2020. Chemotherapy intensity was categorized as high (bolus cisplatin and/or induction chemotherapy), medium (weekly cisplatin), or low (non-cisplatin or RT alone). Standard favorable vs. unfavorable risk was defined using NRG HN005 eligibility criteria. High vs. low relative risk (RR) group was defined using the HNCIG omega score (≥ 0.80 vs. < 0.80), which quantifies the proportion of a patient's overall event risk due to cancer. We used multivariable ordinal logistic regression to estimate effects of age (yrs), sex, performance status (PS), Charlson comorbidity index (CCI), T/N (AJCC 8th), current smoking, and pack-years (> 10 vs. ≤ 10) on treatment allocation. Effects on relative event hazards were estimated using generalized competing event regression.Median follow-up time was 44.2 months. Chemotherapy intensity was high in 206 (54%), medium in 108 (28%), and low in 71 (18%). 280 patients (73%) were unfavorable risk and 197 (51%) were high RR. 178 patients (46%) had discordant risk classification. On univariable analysis, significant predictors of higher intensity chemotherapy (normalized odds ratio (OR)) were CCI 0-1 (OR 1.49, 95% CI: 1.23-1.79), high omega score (OR 1.46; 1.20-1.77), decreased age (OR 1.43; 1.18-1.74), and PS 0 (OR 1.22; 1.01-1.48). Controlling for CCI, higher omega score was associated with significantly higher odds of intensive chemotherapy (OR 1.35; 1.10-1.65, but unfavorable risk (HN005 ineligibility) was not (OR 1.19; 0.98-1.44). Higher omega score was also associated with significantly higher RR for cancer recurrence (Rec) vs. competing mortality (CM) events (relative HR (rHR) 1.76; 1.12-2.75), but unfavorable risk was not (rHR 1.05; 0.63-1.75). Among patients receiving cisplatin, 50 favorable risk patients (58%) had high RR; all of their event risk was due to cancer recurrence (Table). The 110 unfavorable risk patients (48%) with low omega score had significantly lower RR for cancer events compared to the high omega score group (rHR 0.49; 0.29-0.84).Many patients with favorable risk p16+ OPSCC have high relative risk for cancer events, which correlates with a benefit of intensive treatment. The HNCIG omega score is a strong predictor of allocation to intensive chemotherapy and may help identify candidates for deintensification." @default.
• W4387160191 created "2023-09-30" @default.
• W4387160191 creator A5006856468 @default.
• W4387160191 creator A5009352804 @default.
• W4387160191 creator A5013471928 @default.
• W4387160191 creator A5021525793 @default.
• W4387160191 creator A5036816456 @default.
• W4387160191 creator A5038425364 @default.
• W4387160191 creator A5039202077 @default.
• W4387160191 creator A5043780648 @default.
• W4387160191 creator A5043961879 @default.
• W4387160191 creator A5044870790 @default.
• W4387160191 creator A5053309709 @default.
• W4387160191 creator A5056133341 @default.
• W4387160191 creator A5057038406 @default.
• W4387160191 creator A5058684304 @default.
• W4387160191 creator A5073087299 @default.
• W4387160191 creator A5085716641 @default.
• W4387160191 creator A5091329688 @default.
• W4387160191 creator A5091553087 @default.
• W4387160191 date "2023-10-01" @default.
• W4387160191 modified "2023-10-17" @default.
• W4387160191 title "Comparison of Standard vs. Relative Risk Models to Define Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer" @default.
• W4387160191 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1979" @default.
• W4387160191 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785830" @default.
• W4387160191 hasPublicationYear "2023" @default.
• W4387160191 type Work @default.
• W4387160191 citedByCount "0" @default.
• W4387160191 crossrefType "journal-article" @default.
• W4387160191 hasAuthorship W4387160191A5006856468 @default.
• W4387160191 hasAuthorship W4387160191A5009352804 @default.
• W4387160191 hasAuthorship W4387160191A5013471928 @default.
• W4387160191 hasAuthorship W4387160191A5021525793 @default.
• W4387160191 hasAuthorship W4387160191A5036816456 @default.
• W4387160191 hasAuthorship W4387160191A5038425364 @default.
• W4387160191 hasAuthorship W4387160191A5039202077 @default.
• W4387160191 hasAuthorship W4387160191A5043780648 @default.
• W4387160191 hasAuthorship W4387160191A5043961879 @default.
• W4387160191 hasAuthorship W4387160191A5044870790 @default.
• W4387160191 hasAuthorship W4387160191A5053309709 @default.
• W4387160191 hasAuthorship W4387160191A5056133341 @default.
• W4387160191 hasAuthorship W4387160191A5057038406 @default.
• W4387160191 hasAuthorship W4387160191A5058684304 @default.
• W4387160191 hasAuthorship W4387160191A5073087299 @default.
• W4387160191 hasAuthorship W4387160191A5085716641 @default.
• W4387160191 hasAuthorship W4387160191A5091329688 @default.
• W4387160191 hasAuthorship W4387160191A5091553087 @default.
• W4387160191 hasConcept C121608353 @default.
• W4387160191 hasConcept C126322002 @default.
• W4387160191 hasConcept C143998085 @default.
• W4387160191 hasConcept C151956035 @default.
• W4387160191 hasConcept C156957248 @default.
• W4387160191 hasConcept C2776530083 @default.
• W4387160191 hasConcept C2776694085 @default.
• W4387160191 hasConcept C2778239845 @default.
• W4387160191 hasConcept C44249647 @default.
• W4387160191 hasConcept C509974204 @default.
• W4387160191 hasConcept C71924100 @default.
• W4387160191 hasConcept C72563966 @default.
• W4387160191 hasConcept C82789193 @default.
• W4387160191 hasConceptScore W4387160191C121608353 @default.
• W4387160191 hasConceptScore W4387160191C126322002 @default.
• W4387160191 hasConceptScore W4387160191C143998085 @default.
• W4387160191 hasConceptScore W4387160191C151956035 @default.
• W4387160191 hasConceptScore W4387160191C156957248 @default.
• W4387160191 hasConceptScore W4387160191C2776530083 @default.
• W4387160191 hasConceptScore W4387160191C2776694085 @default.
• W4387160191 hasConceptScore W4387160191C2778239845 @default.
• W4387160191 hasConceptScore W4387160191C44249647 @default.
• W4387160191 hasConceptScore W4387160191C509974204 @default.
• W4387160191 hasConceptScore W4387160191C71924100 @default.
• W4387160191 hasConceptScore W4387160191C72563966 @default.
• W4387160191 hasConceptScore W4387160191C82789193 @default.
• W4387160191 hasIssue "2" @default.
• W4387160191 hasLocation W43871601911 @default.
• W4387160191 hasLocation W43871601912 @default.
• W4387160191 hasOpenAccess W4387160191 @default.
• W4387160191 hasPrimaryLocation W43871601911 @default.
• W4387160191 hasRelatedWork W2037611947 @default.
• W4387160191 hasRelatedWork W2044379330 @default.
• W4387160191 hasRelatedWork W2138334887 @default.
• W4387160191 hasRelatedWork W2323473382 @default.
• W4387160191 hasRelatedWork W2335988042 @default.
• W4387160191 hasRelatedWork W2408650435 @default.
• W4387160191 hasRelatedWork W2971695752 @default.
• W4387160191 hasRelatedWork W3010075638 @default.
• W4387160191 hasRelatedWork W363598932 @default.
• W4387160191 hasRelatedWork W4322739880 @default.
• W4387160191 hasVolume "117" @default.
• W4387160191 isParatext "false" @default.
• W4387160191 isRetracted "false" @default.
• W4387160191 workType "article" @default.